Results 61 to 70 of about 16,400 (171)

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

, 2010
This retrospective analysis was conducted to describe the characteristics of nucleoside-naïve hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B, who achieved hepatitis B surface antigen (HBsAg) loss during entecavir or lamivudine ...
A. Gadano, T.-T. Chang, J. Yang, H. Brett-Smith, C.-L. Lai, BrettSmith, H, Lai, CL, Gish, RG, R. De Man, Tamez, R, Gadano, A, R. Tamez, De Man, R, R. G. Gish, F. Poordad, Yang, J, Poordad, F, Chang, TT   +17 more
core   +1 more source

A Case Report of a Special Type of Multiple Myeloma: Kappa Light Chain‐Only

Organ Medicine, Volume 3, Issue 2, Page 119-124, June 2026.
This case illustrates the clinical course of a patient diagnosed with kappa light chain‐only multiple myeloma, a rare subtype of multiple myeloma. Of note, light chain multiple myeloma is characterized by rapid disease progression and severe target organ damage.
Yanhua Dai, Yuanyue Guan, Shiwei Cui, Yuan Gao, Zhipeng Zhao, Rui Li, Li Song, Xiuying Zhao, Runqing Li   +8 more
wiley   +1 more source

Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure [PDF]

, 2019
BACKGROUND AND AIM: Functional cure is the major goal of chronic hepatitis B (CHB) therapy though few biomarkers predict this outcome. HBsAg epitope occupancy can be influenced by therapeutic and immune pressure.
Yuen, L, Deerain, J, Mani Subramanian, Darren Wong, Locarnini, S, Leary, T, Rachel Hammond, Gavin Cloherty, Stephen Locarnini, O’Donnell, T, Renae Walsh, Cloherty, G, Kitrinos, K, Lilly Yuen, Hammond, R, Joshua Deerain, Kathryn Kitrinos, Anuj Gaggar, Tanya O’Donnell, Thomas Leary, Walsh, R, Wong, D, Subramanian, M, Gaggar, A   +23 more
core   +1 more source

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, Volume 5, Issue 2, Page 170-188, June 2026.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis

, 2016
BACKGROUND AND AIMS: Functional cure in chronic hepatitis B requires HBV DNA negativity, HBsAg loss and anti-HBs seroconversion. ARC-520 RNAi drug therapy targets cccDNA derived mRNA, including the full-length HBsAg transcript.
Yuen, L, Deerain, J, Locarnini, SA, Lau, JY, Ferrari, C, Lai, CL, Gish, RG, Given, B, Yuen, MF, Hammond, R, Walsh, R, Hamilton, J, Schluep, T, Chan, HLY   +13 more
core   +1 more source

The Safety of Interferon‐Based Therapies in Chronic Hepatitis B Patients With Compensatory Cirrhosis

Portal Hypertension &Cirrhosis, Volume 5, Issue 2, Page 107-116, June 2026.
While nucleos(t)ide analog (Nuc) therapy is the standard for chronic hepatitis B, pegylated interferon‐alpha (Peg‐IFN‐α) provides unique advantages, including finite treatment duration and long‐term benefits. However, its use in patients with compensated cirrhosis remains limited due to persistent safety concerns about potential decompensation and ...
Qiran Zhang, Taoran Geng, Ruirui You, Huiling Xiang, Ying Guo, Xiaohong Gao, Guojun Li, Qun Zhang, Xiaoping Wu, Haifang Cao, Wenhua Zhang, Jia Shang, Jiawei Geng, Lihong Qu, Shuilin Sun, Xiulan Xue, Rui Zhao, Lihua Zhong, Guohong Ge, Yanbin Wang, Jianqi Lian, Ming Liang, Qing Ye, Xiaoyan Wang, Xiaoqing Guo, Dan Xu, Yiqi Yu, Feng Sun, Chao Qiu, Jiming Zhang, Yuxian Huang, Wenhong Zhang, Xiaolong Qi   +32 more
wiley   +1 more source

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 12, Page 1626-1634, June 2026.
We used an administrative claims dataset to evaluate the relationship between hepatitis B virus (HBV) low‐level viraemia and subsequent liver‐related outcomes in patients with chronic HBV. We found that individuals with HBV low‐level viraemia have an increased risk for liver‐related events (i.e., cirrhosis, decompensation, and hepatocellular carcinoma)
Paul Y. Kwo, Laura E. Telep, Lai San Hong, Ching Yi Chuo, Betty Chiang, Sarjita D. Naik, Catherine T. Frenette, Amanda W. Singer, Anand P. Chokkalingam, Robert J. Wong, Leland J. Yee, Camilla S. Graham   +11 more
wiley   +1 more source

Risk Stratification of Chronic Kidney Disease in Adults Using Noninvasive Fibrosis Tests Based on the American Diabetes Association Algorithm

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5240-5251, June 2026.
ABSTRACT Aims Although the American Diabetes Association (ADA) recently established a diagnostic algorithm for the early detection of liver fibrosis among high‐risk individuals, its implications for chronic kidney disease (CKD) risk stratification remain unclear.
Chan‐Young Jung, Hye Won Lee, Jung Il Lee, Han Ah Lee, Seung Up Kim   +4 more
wiley   +1 more source

Incidence and Characteristics of HBV Reactivation‐Related Events Following HBsAg Seroclearance: Long‐Term Follow‐up of a Population‐Based Cohort in Japan

Hepatology Research, Volume 56, Issue 6, Page 944-955, June 2026.
In a population‐based cohort in Japan, HBV reactivation‐related events were observed after HBsAg seroclearance, including one virologically confirmed hepatic flare occurring spontaneously without chemotherapy or immunosuppression. These findings indicate that HBsAg seroclearance does not always represent complete viral eradication, supporting the need ...
Kazumi Yamasaki, Satoshi Shirahama, Takahiro Yasaka, Shota Yamaguchi, Masashi Mizokami, Junko Tanaka, Hiroaki Okamoto, Hiroshi Yatsuhashi   +7 more
wiley   +1 more source

Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan

Hepatology Research, Volume 56, Issue 6, Page 903-913, June 2026.
Hepatitis B is a viral liver infection that can become chronic, increasing the risk of developing liver cancer and liver failure. Because current treatments rarely cure these problems, researchers are now focusing on a functional cure in which the virus becomes undetectable in blood and stays that way, even after the treatment ends.
Yutaka Handa, Ethan Yichen Lee, Yasuhito Tanaka   +2 more
wiley   +1 more source